Agilis Biotherapeutics LLC, of Cambridge, Mass., said it became the first company to gain an FDA orphan drug designation for a gene therapy for Friedreich’s ataxia. The company’s candidate, AGIL-FA, is focused on delivering corrective DNA to specific CNS cells to restore frataxin protein levels.